Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct research and development expenses and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment (in thousands):

Year Ended December 31, 2018	Generics			Specialty		Corporate and Other			Total Company
Net revenue	$	1,439,031		$	223,960	$	—		$	1,662,991
Cost of goods sold	842,996			103,592		—			946,588
Gross profit	596,035			120,368		—			716,403
Selling, general and administrative	68,426			49,465		112,544			230,435
Research and development	183,412			10,778		—			194,190
In-process research and development impairment charges	39,259			—		—			39,259
Acquisition, transaction-related and integration expenses	114,622			—		107,196			221,818
Restructuring and asset-related charges	33,943			4,076		18,394			56,413
Intellectual property legal development expenses	15,772			489		—			16,261
Legal settlement gains	(22,300		)	—		—			(22,300		)
Operating income (loss)	$	162,901		$	55,560	$	(238,134	)	$	(19,673	)

Year Ended December 31, 2017	Generics			Specialty		Corporate and Other			Total Company
Net revenue	$	1,033,654		$	—	$	—		$	1,033,654
Cost of goods sold	507,476			—		—			507,476
Gross profit	526,178			—		—			526,178
Selling, general and administrative	56,050			—		52,996			109,046
Research and development	171,420			—		—			171,420
Intellectual property legal development expenses	20,518			—		—			20,518
Legal settlement gains	(29,312		)	—		—			(29,312		)
Acquisition and transaction-related expenses	—			—		9,403			9,403
Operating income (loss)	$	307,502		$	—	$	(62,399	)	$	245,103

Year Ended December 31, 2016	Generics			Specialty		Corporate and Other			Total Company
Net revenue	$	1,018,225		$	—	$	—		$	1,018,225
Cost of goods sold	420,770			—		—			420,770
Gross profit	597,455			—		—			597,455
Selling, general and administrative	69,540			—		49,217			118,757
Research and development	179,019			—		—			179,019
Intellectual property legal development expenses	25,728			—		—			25,728
Legal settlement gains	(11,000		)	—		—			(11,000		)
Acquisition and transaction-related expenses	—			—		70			70
Operating income (loss)	$	334,168		$	—	$	(49,287	)	$	284,881

Schedules of Concentration of Risk

The Company's significant product families, as determined based on net revenue, and their percentage of the Company's consolidated net revenue for each of the years ended December 31, 2018, 2017 and 2016 are set forth below (in thousands, except for percentages):

Segment	Product Family	Year Ended December 31, 2018
		$		%
Generics	Yuvafem-Estradiol	$	130,920	8%
Generics	Diclofenac Sodium Gel	103,131		6%
Specialty	Rytary® family	95,541		6%
Generics	Aspirin; Dipyridamole ER Capsul	78,541		5%
Generics	Epinephrine Auto-Injector family (generic Adrenaclick®)	$	67,529	4%

Segment	Product Family	Year Ended December 31, 2017
		$		%
Generics	Yuvafem-Estradiol	$	130,480	13%
Generics	Diclofenac Sodium Gel	94,395		9%
Generics	Aspirin; Dipyridamole ER Capsul	79,674		8%
Generics	Oseltamivir	37,240		4%
Generics	Ranitidine	$	31,283	3%

Segment	Product Family	Year Ended December 31, 2016
		$		%
Generics	Lidocaine	$	121,832	12%
Generics	Diclofenac Sodium Gel	71,672		7%
Generics	Yuvafem-Estradiol	53,025		5%
Generics	Metaxalone	33,698		3%
Generics	Metformin ER	$	33,420	3%